Details of the Drug

General Information of Drug (ID: DMM7Z6K)

Drug Name
CXA10
Indication
Disease Entry ICD 11 Status REF
Focal segmental glomerulosclerosis MF8Y Phase 2 [1]
Pulmonary arterial hypertension BB01.0 Phase 2 [2]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DF1JO7
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cysteines of Keap1 (KEAP1 Cysteines) TT3Z6Y9 KEAP1_HUMAN Inactivator [3]
Nuclear factor erythroid 2-related factor 2 (Nrf2) TTA6ZN2 NF2L2_HUMAN Activator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Focal segmental glomerulosclerosis
ICD Disease Classification MF8Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Nuclear factor erythroid 2-related factor 2 (Nrf2) DTT NFE2L2 4.75E-12 -0.28 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03422510) FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04053543) CXA-10 Study in Subjects With Pulmonary Arterial Hypertension. U.S. National Institutes of Health.
3 The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.